Join Cognition Therapeutics for a virtual KOL Event, featuring Martin J. Sadowski, MD, PhD, DSci (New York University School of Medicine), Everard (Jort) Vijverberg, MD, PhD (Alzheimer Center Amsterdam and Neuroscience Amsterdam), and Anton Porsteinsson, MD (University of Rochester Alzheimer’s Disease Care, Research and Education Program) who will provide expert insights on the unmet need and the current treatment landscape for Alzheimer’s disease, as well as anti-amyloid beta monoclonal antibody drug launches, and commercial uptake.
The event will also include a discussion on CT1812, Cognition’s novel oral once-daily sigma-2 receptor antagonist designed to displace Aβ oligomers from their binding sites, with details on its mechanism of action, clinical development program in Alzheimer’s disease, and upcoming data milestones.